Johnson & Johnson

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
478160104
SEDOL
2475833
CIK
0000200406
www.jnj.com
LEI:
©
Johnson & Johnson is a Member of Themefolio
          Covid19-STX          
FIGI: BBG000BMHYD1
JNJ
Johnson & Johnson
GICS: 35202010 · Sector: Healthcare · Sub-Sector: Drug Manufacturers—General
AI
PROFILER
NAME
Johnson & Johnson
ISIN
US4781601046
TICKER
JNJ
MIC
XNYS
REUTERS
JNJ.N
BLOOMBERG
JNJ US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
TradingView ActivTrader MT4 MT5
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Thu, 12.12.2024       Johnson & Johnson
US4781601046

Johnson & Johnson (NYSE: JNJ) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 12:00 p.m. (Eastern Time). This live audio webcast will be availa...
Read More
Johnson & Johnson
Technical Analysis Termsheet Terminal
Permalink
Tue, 10.12.2024       Johnson & Johnson
US4781601046

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22nd to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will hos...
Read More
Johnson & Johnson
Technical Analysis Termsheet Terminal
Permalink
Tue, 15.10.2024       Johnson & Johnson
US4781601046

Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2024 of $1.24 per share on the company’s common stock. The dividend is payable on December 10, 2024 to shareholders of record at the close of business on November 26, 2024. The ex-dividend date is November 26, 2024. ...
Read More
Johnson & Johnson
Technical Analysis Termsheet Terminal
Permalink
Tue, 15.10.2024       Johnson & Johnson
US4781601046

Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2024. “Johnson & Johnson’s strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation,” said Joaquin Duato, Chairman and Chief Executive Officer. “During the quarter, we advanced ou...
Read More
Johnson & Johnson
Technical Analysis Termsheet Terminal
Permalink
Thu, 10.10.2024       Johnson & Johnson
US4781601046

Johnson & Johnson (NYSE: JNJ) will participate in the Stifel 2024 Healthcare Conference on Monday, November 18th, at the Lotte New York Palace in New York. Michael Bodner, Group President, Heart Recovery & Circulatory Restoration, will represent the Company in a session scheduled at 10:55 a.m. (Eastern Time). This live audio webcast will ...
Read More
Johnson & Johnson
Technical Analysis Termsheet Terminal
Permalink
Wed, 09.10.2024       Johnson & Johnson
US4781601046

Johnson & Johnson1 (NYSE: JNJ) announced today it has successfully completed the acquisition of V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. V-Wave will operate as part of Johnson & Johnson MedTech. The acquisition of V-Wave extends Johnson & Johnson MedTech’...
Read More
Johnson & Johnson
Technical Analysis Termsheet Terminal
Permalink
Fri, 04.10.2024       Johnson & Johnson
US4781601046

Johnson & Johnson (NYSE: JNJ) will participate in the Guggenheim Global Healthcare Conference on Tuesday, November 12th, at the InterContinental Boston in Boston, MA. Biljana Naumovic, President, Solid Tumor, U.S. Oncology and Mark Wildgust, Vice President, Global Medical Affairs Oncology, will represent the Company in a session scheduled at 1...
Read More
Johnson & Johnson
Technical Analysis Termsheet Terminal
Permalink
Sat, 21.09.2024       Johnson & Johnson
US4781601046

Attorneys representing tens of thousands of women with ovarian cancer linked to use of Johnson & Johnson (NYSE:JNJ) talc products say they will immediately seek dismissal of a pre-packaged bankruptcy that the company filed earlier today in Texas. In its filing, the New Jersey-based pharmaceutical giant claims that approximately 83% of those p...
Read More
Johnson & Johnson
Technical Analysis Termsheet Terminal
Permalink
Fri, 20.09.2024       Johnson & Johnson
US4781601046

Johnson & Johnson (NYSE: JNJ) (the “Company”) announced that its subsidiary, Red River Talc LLC (“Red River”), filed a voluntary prepackaged Chapter 11 bankruptcy case today in the U.S. Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”) to fully and finally resolve all current and future claims related to ovarian canc...
Read More
Johnson & Johnson
Technical Analysis Termsheet Terminal
Permalink
Thu, 05.09.2024       Johnson & Johnson
US4781601046

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 15th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host t...
Read More
Johnson & Johnson
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S